

Prism Medico And Pharmacy

Reg. Office: D-118, Industrial Area, Phase VII, Mohali-160055

Tel: 0172-5020762

Email: investorgrievancewmcl@gmail.com www.prismmedico.com

Date: 27/04/2021

To,

Department of Corporate Services,

BSE LIMITED

P. J. Towers, Dalal Street,

Mumbai - 400 001

Listing Department,

Metropolitan Stock Exchange of India Ltd.

(MSE)

Vibgyor Towers, 4th floor, Plot No C 62, G - Block, Opp. Trident Hotel,

Bandra Kurla Complex,

Bandra (E), Mumbai - 400 098, India. ISIN: INE730E01016

Scrip Code: 512217

Sub.: Approval of Audited Financial Results for the quarter and year ended 31st March, 2021.

Dear Sir,

Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on 27/04/2021 have considered and approved the Audited Financial Statements for the quarter and year ended on 31st March, 2021. In this regards, we are enclosing herewith:

- 1. Audited Financial Results for the quarter and year ended on 31st March, 2021.
- 2. Auditors Report on Audited Financial Results for the quarter and year ended on 31st March, 2021.
- 3. Declaration for Un-Modified Opinion with Audit Report on Audited Financial Results for the quarter and year ended on 31st March, 2021.

Thanking You,

Yours Truly,

For PRISM MEDICO & PHARMACY LIMITED

Sudhanshu Srrvasta

Director

DIN: 08242441

PRISM MEDICO AND PHARMACY LTD. CIN: L51109PB2002PLC047444

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2021 (In Lakhs)

	PARTICULARS	Quarter Ended (Unaudited)			Year Ended	Year Ended (Audited)
		31,03,2021	31.03,2020	Year to date 31.03.2021	31.03.2021	31.03,2020
T	Income Revenue from operations Other income	431.86	477.56	1,676.35	1676.35	2,689.01
_	Total income from operations	431.86	477.56	1,676.35	1,676.35	2,689.01
n	Expenses	3	51			
	Cost of Material Consumed	978.52		2,146.71	2146.71	2569.7
	Change In Inventories	(479.56)	(506.75)	(479.90)	-479.9	. 91.38
	Employee benefit expenses	15.78	4.02	16.76	16.76	21.90
	Finance costs	0.01	0.02	0.02	0.02	0.02
	Depreciation and amortization expenses	0.31	-	1.23	1.23	1,76
	Payment to BSE		10 de la 10		-	2
	Other expenses	2.22	1.89	9.04	9.04	11.05
	Total expenses	517.28	(500.82)	1,693.86	1,693.86	2,695.81
ш	Profit/(Loss) before exceptional items and tax	(85.42)	(23.26)	(17.51)	(17.51)	(6.80)
IV	Exceptional items					
V	Profit/(Loss) before tax	(85.42)	(23,26)	(17.51)	(17.51)	(6.80)
VI	Tax expenses a) Current tax b) Deferred tax b) Mat Credit	4.49		4.51	4,51	1.78
	Net Profit/(Loss) for the period/year	(80.93)	(23.26)	(13.00)	(13,00)	(5.02)
VIII	Other comprehensive income (net of tax) Items that will not be reclassified to profit or loss: i) Remeasurement of post employment benefit obligations ii) Income-tax relating to items that will not be reclassified to profit or loss Total other comprehensive income			-	-	(3.02)
IX	Total comprehensive income for the period/year (VII+VIII)	(80.93)	(23.26)	(13,00)	(13.00)	(5.02)
X	Paid-up equity share capital (face value of the share shall be indicated)	606.34	606.34	606.34	606,34	606,34
XI	Other equity (excluding revaluation reserve)	686.25	772.22	686.25	686.25	699.25
XII	EPS in Rs. (Face Value of Rs.10/- each)* -Basic -Diluted	(0.13) (0.13)	(0.03) (0.03)	(0.02) (0.02)	(0.02) (0.02)	(0.01) (0.01)

Notes:

- The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 27th April 2021 after being reviewed by the Audit Committee.
- 2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind A5) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2017.
- The company is having single segment in accordance with IND AS 108 "operating segments" and therefore segment reporting is not applicable to the Company.

FOR & ON BEHALF OF THE BOARD PRISM MEDICO AND WHARMACY LTD.

SUDHANSHU SRIVASTAV

Director

DIN: 08242441

Place : Mohali

Date: 27/04/2021

Statement of Assets and Liabilities For the Year ended on 31st March 2021

P	ARTICULARS	31ST MARCH 2021	in Rs.
I. ASSETS		3131 MARCH 2021	31ST MARCH 2020
	Non - Current Assets		
8.00	(a) Property, Plant and Equipment	553,409	677,381
	b) Financial Assets	000/109	077,001
	(1) Non-Current Investments	19,380,000	19,380,000
	b) Deffered Tax Asset	588,128	136,134
(2)	Current Assets		
	(a) Inventories	48,466,240	475,729
	b) Financial Assets		
	(1) Cash & Cash Equivalent	841,329	1,117,555
	(2) Short Term Loans and advances	10,115,337	10,356,338
	(3) Trade Receivables	135,139,412	183,361,367
	(c) Other Current Asset	336,741	336,741
	TOTAL Rs. AL Rs.	215420596	215841245
ΗЕ	QUITY AND LIABILITIES		
(1)	Equity		
	(a)Equity Share Capital	60,634,280	60,634,280
	(b Other Equity	68,625,164	69,925,246
(2)	Current Liabilities		從
	a) Financial Liabilties		
	(1) Trade Payables	84,438,878	84,480,968
	(b) Other Current Liabilities	1,722,275	800,750
	TOTAL Rs. AL Rs.	215420596	215841245



PRISM MEDICO AND PHARMACY LTD Cash Flow Statement for the year ended 31st March 2021							
A.	Cash Flow from Operating Activities:	/4 7EQ 07C COV	(681,169.59)				
	Profit before tax for the year	(1,752,076.68)	(001,109.09)				
	Adjustments for :	123,971.20	176,180.81				
	Depreciation & Amortization	2,465,00	2,494				
	Interest & Finance Charges	2,403.00	2,404				
	Operating Profit Before Prior Period Items and Working Capital Changes	(1,625,640.48)	(502,494.78				
	Operating Profit Before Working Capital Changes	(1,625,640.48)	(502,494.78				
	Adjustments for:		100 000 000				
	Decrease/(Increase) in Receivables	48,221,955	(99,995,666				
	Inventories	(47,990,511)	9,139,806				
	Other Current Assets	004 505	(247,860.00				
	Other Current Liabilities	921,525	(543,033				
	Increase/(Decrease) in Trade Payables	(42,090)	48,808,660				
	Cash Generated from Gperations	(514,762)	(43,340,587.27				
	Income Tax Paid		307,308.00				
	Net Clash from Operating Activities	(514,762)	(43,647,895				
В.	Cash Flow from Investing Activities:						
-	Investments		80,619,990				
	Loans & Advances given	241,000.50	(37,027,863.71				
	Net Cash (used)/Genretated in Investing Activities	241,001	43,592,126				
e and							
C.	Cash Flow from Financing Activities:						
	Proceed from Share Capital						
	Proceeds/(Repayment) of Long Term Borrowings						
	Proceeds/(Repayment) of Short Term Borrowings	(0.405.00)	(0.404.00				
	Interest and Other Finance Costs paid	(2,465.00)	(2,494.00				
	Net Cash (Used)/Generated in Financing Activities	(2,465.00)	(2,494.00				
	Net Increase in Cash and Cash Equivalents (A)+(B)+(C)	(276,227)	(58,263				
	Opening Cash and Cash Equivalents (A)+(B)+(C)	1,117,556	1,175,819.31				
	Closing Cash and Cash Equivalents	841,329	1,117,556				

FOR PRISM MEDICO AND PHARMACY LTD

Gursimran Singh CFO

DIRECTOR

Sehejbir Singh Bhatia

DIRECTOR

Samoer Gupta

CS

DATE: 27/04/2021 PLACE: MOHALI



CIN: L51109PB2002PLC047444



Prism Medico And Pharmacy Limited

Reg. Office: D-118, Industrial Area, Phase VII, Mohali-160055

Tel: 0172-5020762

Email: investorgrievancewmcl@gmail.com www.prismmedico.com

DECLARATION

Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 20151

Pursuant to the requirement as specified by regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended by SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016 it is hereby declared that the Auditors Report for the Financial Year ended on March 31, 2021 contains unmodified opinion as provided under the Independent Auditor's Report which is attached herewith for your reference.

You are kindly requested to take the above declaration in your records.

For PRISM MEDICO & PHARMACY LIMITED

Sudhanshu Srivastav

Director

DIN: 08242441



Harjeet Parvesh & Company CHARTERED ACCOUNTANTS

(A PEER REVIEWED FIRM)

Independent Auditor's Report

To

The Members of M/s Prism Medico & Pharmacy Limited

Opinion

We have audited the accompanying standalone financial statements of M/s Prism Medico & Pharmacy Limited which comprise the Balance Sheet as at March 31, 2021, the Statement of Profit and Loss (statement of changes in equity), Cash Flow Statement for the year then ended, notes to the financial statements and a summary of significant accounting policies and other explanatory information. These financial statements are the responsibility of the company's management. Our responsibility is to express an opinion on these financial statements based on our audit.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid (Standalone) financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2021, and its Profit ,(changes in equity) for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key Audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Management's Responsibility for the StandaloneFinancial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, (changes in equity) and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of

appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the audit of the Standalone Financial Statements

Our responsibility is to express an opinion on these (Standalone) financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Report on Other Legal and Regulatory Requirements

- As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the Annexure-A, a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
- 2. As required by section 143 (3) of the Act, we report that:
- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
- b) In our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- c) The Balance Sheet, the Statement of Profit and Loss dealt with by this Report are in agreement with the books of account
- d) In our opinion, the aforesaid (Standalone) financial statements comply with the Accounting Standards specified under section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of written representations received from the directors as on March 31, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.
- f) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company does not have any pending litigations which would impact its financial position.

- ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For Harjeet Parvesh & Co.

Chartered Accountants

FRN: 017437N

CA Konica Madan

Partner

M.No 547759

UDIN: - 21547759AAAAAJ7587

Date: 27/04/2021

Place: MOHALI

Annexure A" to the Independent Auditors' Report

Referred to in paragraph 1 under the heading 'Report on Other Legal & Regulatory Requirement' of our report of even date to the financial statements of the Company for the year ended March 31, 2021:

- 1) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets;
- (b) The Fixed Assets have been physically verified by the management in a phased manner, designed to cover all the items over a period of three years, which in our opinion, is reasonable having regard to the size of the company and nature of its business. Pursuant to the program, a portion of the fixed asset has been physically verified by the management during the year and no material discrepancies between the books records and the physical fixed assets have been noticed.
- (c) The title deeds of immovable properties are held in the name of the company.
- 2) (a) The Management has conducted Physical verification of inventory at reasonable intervals.
 - (b) There were No Discrepancies noticed on physical verification of the inventory.
- 3) The Company has not granted any loans, secured or unsecured to companies, firms, Limited Liability partnerships or other parties covered in the Register maintained under section 189 of the Act. Accordingly, the provisions of clause 3 (iii) (a) to (C) of the Order are not applicable to the Company and hence not commented upon.
- 4) In our opinion and according to the information and explanations given to us, the company has complied with the provisions of section 185 and 186 of the Companies Act, 2013 In respect of loans, investments, guarantees, and security.

- 5) The Company has not accepted deposits from the public and hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the public are not applicable.
- 6) As informed to us, the maintenance of Cost Records has not been specified by the Central Government under sub-section (1) of Section 148 of the Act, in respect of the activities carried on by the company.
- 7) (a) According to information and explanations given to us and on the basis of our examination of the books of account, and records, the Company has been generally regular in depositing undisputed statutory dues including Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs, Duty of Excise, Goods and Service Tax, Cess and any other statutory dues with the appropriate authorities. According to the information and explanations given to us, no undisputed amounts payable in respect of the above were in arrears as at March 31, 2021 for a period of more than six months from the date on when they become payable.
- b) According to the information and explanation given to us, there are no dues of income tax, GST, duty of customs, duty of excise, value added tax outstanding on account of any dispute.
- 8) In our opinion and according to the information and explanations given to us, the Company has not defaulted in the repayment of dues to banks. The Company has not taken any loan either from financial institutions or from the government and has not issued any debentures.
- 9) Based upon the audit procedures performed and the information and explanations given by the management, the company has not raised any moneys by way of initial public offer or further public

offer including debt instruments and term loans. Accordingly, the provisions of clause 3 (ix) of the Order are not applicable to the Company and hence not commented upon.

- 10) Based upon the audit procedures performed and the information and explanations given by the management, we report that no fraud by the Company or on the company by its officers or employees has been noticed or reported during the year.
- 11) Based upon the audit procedures performed and the information and explanations given by the management, the managerial remuneration has been paid or provided in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Companies Act;
- 12) In our opinion, the Company is not a Nidhi Company. Therefore, the provisions of clause (xii) of the Order are not applicable to the Company.
- 13) In our opinion, all transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 and the details have been disclosed in the Financial Statements as required by the applicable accounting standards.
- 14) Based upon the audit procedures performed and the information and explanations given by the management, the company has not made any preferential allotment of shares or private placement of shares or fully or partly convertible debentures during the year under review. Accordingly, the provisions of clause 3 (xiv) of the Order are not applicable to the Company and hence not commented upon.

15) Based upon the audit procedures performed and the information and explanations given by

the management, the company has not entered into any non-cash transactions with directors or

persons connected with him. Accordingly, the provisions of clause (xv) of the Order are not

applicable to the Company and hence not commented upon.

16) In our opinion, the company is not required to be registered under section 45 IA of the

Reserve Bank of India Act, 1934 and accordingly, the provisions of clause (xvi) of the Order

are not applicable to the Company and hence not commented upon.

For Harjeet Parvesh & Co.

Chartered Accountants

FRN: 017437N

CA Konica Madan

Partner

M.No 547759

UDIN: - 21547759AAAAAJ7587

Date: 27/04/2021

vato. Ziro

Place: MOHALI

Annexure B" to the Independent Auditor's Report of even date on the Financial Statements of M/s Prism Medico & Pharmacy Limited

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of M/s Ajooni Biotech

Limited ("the Company") as of March 31, 2021 in conjunction with our audit of the standalone

financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial

controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021.

For Harjeet Parvesh & Co.

Chartered Accountants

RN: 017437N

CA Konica Madan

Partner

M.No 547759

UDIN: - 21547759AAAAAJ7587

Date: 27/04/2021

Place: MOHALI